LAU-7b is an oral compound. It is a form of the retinoid fenretinide. Retinoids are a group of compounds related to vitamin A. Fenretinide may help reduce the inflammatory response in the lungs of people with CF.
A phase 2 study will begin in 2017 to test the safety and effectiveness of LAU-7b in people with CF.
This program is sponsored by Laurent Pharmaceuticals. It is being conducted within the Cystic Fibrosis Foundation's Therapeutics Development Network.
Contact us about LAU-7b >